Could a lower dose of Clot-Buster be safer for lung infections?
NCT ID NCT05766124
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a lower dose (2.5 mg) of a clot-busting drug called tPA works as well as the standard dose (10 mg) for treating pleural infections, which cause fluid buildup around the lungs. The drug is given through a chest tube along with another enzyme to help drain the infection. The goal is to see if the lower dose reduces bleeding risk while still being effective. The study involves 30 adults with unresolved pleural infections and will track their recovery for 3 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tissue plasminogen activator (tPA, also known as Alteplase) with deoxyribonucleases (DNase)
What this could lead to
If successful, this could point toward a safer, equally effective dose of tPA for treating pleural infections, reducing bleeding complications.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply broadly. The lower dose might be less effective, and bleeding risks remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese University of Hong Kong
RECRUITINGHong Kong, Hong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••